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The treatment of municipal wastewater in the Arctic is challenging due to a variety of 23 
financial, operational, climatic and technical issues. To better understand the efficacy of current 24 
wastewater treatment in this region and the hazard posed to receiving waters, we assessed the 25 
occurrence of contaminants (i.e., pharmaceuticals, antibiotic resistance genes and nutrients) as 26 
they moved through a lagoon-based treatment system in Cambridge Bay in Nunavut, Canada. 27 
Wastewater treatment in this community is performed by the use of a lagoon-tundra wetland 28 
system that is discharged into the marine environment and is representative of current common 29 
practices throughout the region. In 2014, samples were collected before and during lagoon 30 
discharge from two locations in the main lagoon, one location downstream from the lagoon 31 
effluent and three locations offshore. Grab samples were collected to measure nutrients (e.g. total 32 
nitrogen and phosphorus) and the presence of antibiotic resistance gene-bearing microbes, and 33 
Polar Organic Chemical Integrative Samplers (POCIS) were deployed to collect passively 34 
organic contaminants in all locations. A total of six pharmaceuticals were detected from a screen 35 
of twenty-eight analytes during the study: atenolol, carbamazepine, clarithromycin, metoprolol, 36 
sulfamethoxazole and trimethoprim. The greatest concentrations of nutrients, antibiotic 37 
resistance genes (ARGs) and pharmaceuticals were found in sampling locations within the 38 
treatment lagoon. Offshore of the release point, we observed limited to no detection of 39 
pharmaceuticals and ARGs and no change in total nitrogen and phosphorus from pre-release. We 40 
conclude that the current concentrations of monitored pharmaceuticals do not pose a significant 41 
hazard at this time to aquatic organisms in Cambridge Bay. 42 
 43 




Capsule statement: Baseline exposure data for nutrients, antibiotic resistance genes and 46 
pharmaceuticals in surface and seawater at Cambridge Bay is introduced, alongside an 47 
ecotoxicological hazard assessment.  48 
 49 
1. Introduction 50 
Organic contaminants in wastewater effluents, including pharmaceuticals, are released to 51 
aquatic ecosystems and have been found to pose a hazard under certain conditions to receiving 52 
waters; this poses a challenge for current wastewater treatment practices in many regions (Fent et 53 
al., 2006). Some pharmaceuticals such as anti-inflammatory drugs, antidepressants and 54 
antibiotics are not completely eliminated in the human body and can therefore enter the sewage 55 
system as parent compounds and their biologically active metabolites (Vasskog et al., 2009). 56 
Many current wastewater treatment systems are not specifically designed to eliminate organic 57 
contaminants and, as a consequence, many of these pollutants are able to persist through 58 
wastewater treatment processes (Gunnarsdottir et al., 2013). In addition, monitoring actions for 59 
most micropollutants have not been well established in most wastewater treatment facilities 60 
(Bolong et al., 2009). Another concern is the presence of organisms that carry antibiotic 61 
resistance genes (ARGs), which can threaten public health (Rowan, 2011). Antibiotic resistance 62 
genes have been detected in the environment as a result of the prevalent human and veterinary 63 
use of antibacterial and antimicrobial products (Kummerer, 2009). Nutrient enrichment has also 64 
been a potential hazard to the aquatic environment with increasing eutrophication in freshwater 65 
and enclosed marine systems downstream of areas of urbanization (Smith, 2003). Algal blooms 66 
can block light from getting into the aquatic environment. With enough overgrowth, they can 67 
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prevent oxygen from getting into the water, thereby, endangering plants and animals. While the 68 
releases of effluents have been characterized for many countries and regions of the world (Luo et 69 
al., 2014), little to no work has been performed to quantify organic micropollutants and their risk 70 
in polar regions because of the difficulties associated with travel logistics and sample holding 71 
limitations. Therefore, the collection of sample replicates and comprehensive datasets suitable 72 
for statistical analysis is highly constrained in these regions. As a consequence, there is a lack of 73 
understanding of environmental risks, system performance and treatment mechanisms associated 74 
with the treatment systems in polar regions (Chouinard et al., 2014).  75 
Some studies have been performed in Arctic environments for the screening of 76 
pharmaceuticals and personal care products in wastewaters. For example, Weigel et al. (2004)  77 
studied the prevalence of selected pharmaceuticals in different sewage samples from Troms¿ in 78 
Norway as well as in the seawater from Troms¿-sound, the recipient of wastewater. The selected 79 
pharmaceuticals were, among others, ibuprofen, and its metabolites, and the insect repellent 80 
N,N-diethyl-3-toluamide (DEET) as well as caffeine, which was included as a tracer for 81 
domestic sewage. Emnet et al. (2015) studied the occurrence of personal care products in two 82 
Antarctic research stations, detecting six analytes in treated wastewaters, including the UV filters 83 
4-methyl-bezylidene camphor, 2-hydroxy-4-methoxybenzophenone and 2,4-84 
dihydroxybenzophenone, the plastic monomer 2,2-bis(4-hydroxyphenyl)-propane, the steroid 85 
hormone estrone and the antimicrobial triclosan. These compounds were detected at 86 
concentrations comparable to those reported for international coastal waters adjacent to 87 
significantly greater human populations (Balmer et al., 2005). 88 
In many regions of the Arctic, the release of sewage with minimum or no treatment can 89 
have consequences for the receiving environment due to high vulnerability of the Arctic 90 
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ecosystem to environmental contaminants (Gunnarsdottir et al., 2013). Kallenborn et al. (2008) 91 
reported that pharmaceutical residues are degraded slower in Arctic environments compared to 92 
release scenarios in lower latitudes. In their study a set of nine different antidepressants and their 93 
transformation products were analyzed in receiving seawater from two locations in Norway, one 94 
of them in a northern region. Increased environmental stability of these compounds was detected 95 
in the Arctic environment compared to the temperate location. The removal of pharmaceutical 96 
residues by photodegradation is limited during the Arctic polar night and the intensity of sunlight 97 
(even continuously during periods of midnight sun) at other times of the year are less intense 98 
than that of more temperate regions. Both limited photodegradation during the winter and the 99 
cold Arctic climate can slow down the degradation rate of pharmaceutical residues in the 100 
environment (Schwarzenbach et al., 2003). 101 
Arctic communities frequently experience several challenges in order to perform adequate 102 
treatment of their wastewaters. Characteristics such as geographical remoteness, adverse weather 103 
and lack of basic services are common in many communities and make wastewater treatment, 104 
whenever possible, a difficult task (Yates et al., 2012). The scarcity of accredited laboratories for 105 
compliance testing and the necessity for trained personnel to manage wastewater facilities are 106 
challenges that need to be overcome by these communities on a daily basis. The subsistence 107 
fishery is a significant industry in many Arctic coastal regions, for which pollutant contamination 108 
of marine species exploited for human consumption is a major concern. Exposure to 109 
micropollutants and their uptake in the food web can have hazardous effects on human health 110 
and the environment through bioaccumulation and biomagnification of chemicals (Gunnarsdottir 111 
et al., 2013).  112 
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The Canada Health Act ensures that the majority of health services are publicly funded for 113 
all Canadians, with administration occurring at the provincial and territorial level. Despite this 114 
universality of health care, some differences occur in the health status of aboriginal and non-115 
aboriginal Canadians. First Nations populations experience greater rates of mental illness, 116 
suicide, diabetes, asthma, cardiovascular disease, tuberculosis, hepatitis, syphilis and HIV/AIDS 117 
than non-aboriginal populations (Romain, 2013). This can influence the amount of 118 
pharmaceuticals that are needed to treat these diseases in Northern Canadian communities. 119 
To begin to address the need for knowledge about wastewater contaminants exposure in 120 
the Arctic, it is needed to quantify the types and quantities of nutrients and micropollutants in 121 
lagoon discharge effluents and receiving waters. Such an effort would allow a partial 122 
understanding of the possible hazards associated with wastewater discharges into receiving 123 
environments.  In this study, we examined the efficacy of wastewater treatment under arctic 124 
conditions, by assessing the occurrence of selected wastewater contaminants attenuation and 125 
release from a wastewater treatment facility in Cambridge Bay, Nunavut, Canada. Our objectives 126 
were: first, to obtain recent exposure data for the wastewater contaminants in Cambridge Bay, 127 
regarding to the concentrations of nutrients (total nitrogen and phosphorus), ARGs and 128 
pharmaceuticals; and second, to provide a baseline of the current state of wastewater treatment in 129 
Cambridge Bay, in anticipation of the eventual instalment, expected by 2017, of the Canadian 130 
High Arctic Research Station (CHARS), a scientific facility for Arctic research,  as well for 131 
expanding populations in the Arctic in general. Of particular interest was the exposure data at the 132 
water intake point that CHARS will eventually use for research purposes. We were also 133 
interested on assessing the facility for evidence of any leaky sewage infrastructures, specifically 134 
at Finger Bay. We hypothesize that the wastewater contaminants in Cambridge Bay do not pose 135 
7 
 
a significant risk at this time to the marine environment, and that the lagoon-wetland system in 136 
this community has the ability to perform partial attenuation on nutrients, pharmaceuticals and 137 
antibiotic resistance genes. 138 
 139 
2. Materials and Methods 140 
2.1. Study location 141 
Cambridge Bay is located in the territory of Nunavut in the Canadian Arctic. It has a 142 
population of approximately 1,400. Mean monthly temperatures range from a maximum and 143 
minimum, respectively, of -28 ¡C and -35 ¡C in January to 13 ¡C and 5 ¡C in July (Government 144 
of Canada, 2014).  In 2017CHARS will become operational. This will likely have an impact in 145 
the community in terms of increases in population and use of water resources, including 146 
wastewater disposal and treatment. This study provides a baseline for current wastewater impacts 147 
prior to CHARSÕ opening. 148 
The wastewater system monitored at Cambridge Bay is comprised of a wastewater lagoon, 149 
formerly a series of natural lakes, that performs primary treatment and is discharged once a year, 150 
during the summer, into a small hydrologically-isolated natural tundra wetland. Wastewater then 151 
is released through an open channel into the marine environment. Municipal sewage from 152 
household sewage tanks is regularly transported to the lagoon by sewage trucks that perform 153 
dumping runs year-round. 154 
2.2. Sample collection 155 
The selection of sampling sites was done in consultation with local municipal authorities 156 
with an overarching aim of characterizing the composition of wastewaters and receiving waters 157 
for the target analytes. We were also interested in assessing risk to CHARS intake by wastewater 158 
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and the possibility of sewage leakiness into Finger Bay. Water was sampled from six selected 159 
locations around the study site (Figure 1). These were: approximately 20 meters away from a 160 
new wastewater drop off point (Lagoon Input 1); approximately 20 meters away from an older 161 
drop off point (Lagoon Input 2); at the outflow of the natural tundra wetland (Wetland); 162 
approximately 100 meters offshore of the primary discharge point (approximately 100 meters 163 
from the Wetland site) to the bay (Outfall); at the seawater intake point for CHARS studies 164 
(CHARS); and at a previously used run-off discharge point culvert, currently closed, located 165 
around 300 meters west from the main discharge point (Finger Bay). No significant rain events 166 
were registered during the sampling. Pharmaceuticals were passively sampled using triplicate 167 
POCIS (Environmental Sampling Technologies, St Joseph, MO) in the ÒpharmaceuticalÓ 168 
configuration as described by MacLeod and Wong (2010). Sampling was performed both before 169 
and during release of wastewater from the lagoon. Pre-release POCIS sampling was performed 170 
from July 25 to August 8, 2014 for inland locations, and from July 26 to August 9 for offshore 171 
locations. Wastewater release occurred from August 28 to September 5 with POCIS sampling 172 
performed from August 29 to September 8 at all locations. Grab-sampling for nutrients 173 
(composite sample) and antibiotic resistance genes (ARGs; triplicate sample) was conducted on 174 
July 25 in the pre-release stage, and on September 3 during release. Field blanks immersed in 175 
nanopure water (18 MΩ-cm, Millipore, Billerica, MA) in the appropriate containers were opened 176 
during sampling to determine the extent of contamination. Samples were kept on ice within 24 177 
hours after the sampling for transport to the local laboratory, and shipped on ice back to 178 
Winnipeg for processing.Samples for nutrients were collected in 50 mL falcon tubes. Personnel 179 
wore gloves disinfected with 70% isopropanol while handling ARGs samples which were 180 
collected in autoclaved 500 mL polyethylene bottles pre-release (July 25) and during release 181 
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(September 3) from all sampling locations. Bottles were rinsed three times with sample water 182 
before being filled to the top with no headspace. Field blanks filled with nanopure water (18 183 
MΩ-cm, Millipore, Billerica, MA) in the appropriate containers were opened during sampling to 184 
determine the extent of contamination. Samples were kept on ice within 24 hours after the 185 
sampling for transport to the laboratory, where ARGs samples were filtered in a sterile 186 
environment. These filters were kept at -20¡C until shipment to the University of Strathclyde for 187 
antibiotic resistance genes analysis. 188 
  189 
2.3. Determination of pharmaceuticals and nutrients 190 
We followed the methods of Carlson et al., (2013), for the analysis of pharmaceuticals. 191 
Ultra high-performance liquid chromatography-tandem mass spectrometry (UHPLC/MS/MS) 192 
with isotope dilution was used to quantify chemicals of interest in water samples. These 193 
compounds included a suite of twenty-eight commonly-used micropollutants frequently found in 194 
wastewaters (Fatta-Kassinos et al., 2011), including β-blockers (e.g. metoprolol); antidepressants 195 
(e.g. fluoxetine); anticonvulsant drugs (e.g. carbamazepine) and macrolide (e.g. clarithromycin) 196 
and sulfonamide (e.g. sulfamethazine) antibiotics. Limits of quantification (LOQ) are found in 197 
Table S1, and other quality assurance/quality control parameters details in Carlson et al. (2013). 198 
Time-weighed average (TWA) concentrations were calculated by dividing the determined mass 199 
of chemical (ng) in the sampler by the sampling rate (L/d) times the deployment time (d) for all 200 
detected pharmaceuticals, making use of sampling rates (Table S2) found in the literature 201 
(MacLeod et al., 2007; Bartelt-Hunt et al., 2011). Concentrations of nutrients (e.g. total nitrogen 202 





2.4. Hazard assessment for detected pharmaceuticals 206 
A hazard assessment was performed for detected compounds by calculating hazard 207 
quotients (HQs) using standard tests and endpoints from aquatic toxicological studies, 208 
particularly for primary producers, invertebrates and fish. Briefly, estimates for effective 209 
concentrations (EC50) or lethal concentrations (LC50) were obtained through a literature search. 210 
For added conservatism, we employed an uncertainty factor of 1000 to the lowest EC50 or LC50 211 
(Waiser et al., 2012). The maximum measured environmental concentration was then divided by 212 
the lowest reported effect concentration (typically freshwater, as marine organism tests were 213 
lacking) to obtain the hazard quotient. Hazard quotients greater than 1 were considered to be of 214 
concern while those compounds with HQ values less than 1 were considered  less likelyto pose a 215 
concern. 216 
 217 
2.5. Determination of antibiotic resistance genes 218 
Antibiotic resistance genes were quantified from cells harvested on filters following cell 219 
disruption (FastPrep, MP Biomedicals; 2 cycles at 30 s each at 6.0 setting) and DNA purification 220 
(MoBio PowerClean Soil DNA kit; Cambio, Cambridge, UK), similar to methods previously 221 
used (Anderson et al., 2015; Cardinal et al., 2014). A multiplex assay was used to target an array 222 
of tetracycline resistant genes (Ng et al., 2001), sulfonamide resistant genes (Pei et al., 2006) and 223 
16S-rRNA was quantified as a measure of Ôtotal bacteriaÕ. Quantitative PCR was conducted 224 
using a BioRad iQ cycler (BioRad, Hercules, CA) using ssoFast EvaGreen reagents (BioRad) 225 
and 500 nM primer concentrations. All samples were diluted 1:100 with molecular grade water, 226 
as reactions were predetermined to be most efficient at those sample concentrations; standards 227 
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and post-analytical melting curves were generated (Smith et al., 2004) to verify PCR reactions 228 
quality and quantify results. 229 
 230 
2.6. Statistical analysis 231 
Changes in concentrations of pharmaceuticals, as well as abundance of ARGs, from before 232 
and during release were assessed using a StudentÕs paired t-test. Concentration data are presented 233 
as mean ± standard deviation (St. Dev) unless otherwise indicated. Differences were considered 234 
significant at p<0.05. 235 
 236 
 237 
Results and Discussion 238 
3.1. Nutrients  239 
Nutrient samples had to be combined in order to measure concentrations at many sites, 240 
particularly those offshore given very low levels there (Table 1). Thus, only a single 241 
measurement was made per site per sampling time, so our discussion of changes in 242 
concentrations is qualitative in nature. 243 
Total nitrogen showed values over 10 mg/L for the lagoon sites both before and during 244 
release measurements. Concentrations at Lagoon Input 1 and Lagoon Input 2 showed similar 245 
levels at both times, with the Wetland site having an increase in concentration after the 246 
wastewater discharge started. There was no apparent reduction in the concentration of nitrogen in 247 
the lagoon or the wetland in the two time periods. Locations offshore (e.g. Outfall, CHARS) 248 
showed much lower concentrations. Total phosphorus levels were approximately 2 mg/L for 249 
both lagoon sites prior to wastewater discharge. After the discharge commenced, phosphorus 250 
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levels in the wetland were elevated to approximately 2 mg/L as well, with no apparent reduction 251 
from additional wetland treatment.  Phosphorus levels appear to be greater and nitrogen values 252 
appear to be lesser than the maximum values recommended for Canadian provinces such as 253 
Manitoba, in which limits of 1 mg/L total phosphorus and 15 mg/L total nitrogen exist for 254 
wastewater effluents discharged to a water body (Manitoba Water Stewardship, 2011). However, 255 
policies for communities in the far north have not yet been defined and a joint governmental 256 
commission has been assigned to define them by 2019 (CCME, 2014). Considerable dilution was 257 
observed for all locations offshore (e.g. Outfall, CHARS), which was consistent with the 258 
nitrogen measurements. Finger Bay showed reduced levels for both total nitrogen and 259 
phosphorus, which suggests that there is little possibility of runoff from the main lagoon to this 260 
location contrary to prior speculations that this was a route of contamination from the lagoon to 261 
the bay. The levels of phosphorus we measured pre-release are comparable to that in the water 262 
column at the center of Cambridge Bay and at Dease Strait, a waterway immediately west of 263 
Cambridge Bay (0.01-0.04 mg/L, C. J. Mundy, unpublished data).  Concentrations of phosphorus 264 
at the Outfall site are roughly twice those levels, suggesting localized effects of phosphorus that 265 
are not evident at points farther away in the bay (Table 1).  While nutrient levels during release 266 
are likely locally elevated relative to concentrations in the greater Canadian Arctic (Tremblay et 267 
al., 2015), more work is warranted to examine to what extent these added nutrients may 268 
influence the local ecosystem of Cambridge Bay and Dease Strait. 269 
No apparent nutrient removal was observed during discharge as a result of lagoon-wetland 270 
treatment. As noted, statistical analysis of nutrient concentrations was not possible. Nor can we 271 
rule out the possibility that nutrient concentrations may have been affected by heterogeneous 272 
distributions within different locations of the lagoon. That having been said, the data obtained in 273 
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this study differ from the results obtained in a previous work by Yates et al. (2012), in which 274 
three larger lagoon-wetland systems in Nunavut (Arviat, Whale Cove and Coral Harbour) were 275 
studied, observing reductions up to 84-99% for NH3-N and 80-99% for total phosphorus. It is 276 
known that the community of Arviat make use of berms and channels to direct wastewater flow 277 
away from the ocean and to keep a longer residence time in the wetland (Wooton et al., 2008), 278 
whereas in the Cambridge Bay wetland the residence time of wastewater is limited by the 279 
landscape topography and the scarce available vegetation. It is yet unclear which mechanisms 280 
play the most important role in wastewater treatment in the Arctic. Wetland size and vegetation 281 
coverage as well as the potential for filtration and sedimentation of suspended solids and 282 
adsorption of nutrients within the soil and water column can play a significant role. 283 
 284 
3.2. Pharmaceuticals 285 
Of the screened twenty-eight organic micropollutants, only six pharmaceuticals were 286 
detected above their LOQ at any of the locations. These were atenolol, clarithromycin, 287 
metoprolol, sulfamethoxazole, trimethoprim and carbamazepine, detected at least once in ng/L 288 
levels (Figure 2). For the detected pharmaceuticals, the greatest concentrations were measured at 289 
the Lagoon Input 1 and 2 sites, although some differences in concentration could be seen 290 
between both of the dumping sites. Most locations offshore experienced considerable dilution 291 
with seawater, which was reflected in significantly lower concentrations for all of the passively 292 
sampled contaminants at Outfall, CHARS and Finger Bay. Although POCIS deployment times 293 
were different before and during discharge (14 days versus 9 days), steady state conditions for 294 
POCIS are typically reached within six days (Vermeirssen et al., 2012) 295 
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The greatest concentration of atenolol was 97 ng/L (Lagoon Input 1). Detected levels were 296 
significantly different (p<0.05) between Lagoon Input 1 and Lagoon Input 2 sites both before 297 
and during the discharge. There was a significant reduction of 45% observed between Lagoon 298 
Input 2 and Wetland (p<0.05) during the wastewater release, and heavy dilution at locations 299 
offshore, with most sites observed to be at non-detectable levels. These results suggest processes 300 
within the wetland (e.g. sorption to plants, microbial degradation) may reduce concentrations of 301 
atenolol under Arctic conditions. A more efficient removal of atenolol has been observed in 302 
more southern locations in Canada, with removal rates up to 98% for example within a sewage 303 
lagoon in Dunnottar, Manitoba under temperate conditions (Anderson et al., 2015).  304 
Concentrations of carbamazepine were generally below 100 ng/L in both lagoon sites, with 305 
greater concentrations reported in the Wetland site both before and during discharge. No 306 
apparent removal was observed as a result of wastewater passage through the treatment wetland 307 
(p<0.05). Offshore locations showed levels below LOQ. Persistence of carbamazepine during the 308 
Arctic winter was observed, with a concentration of 116 ng/L in the hydrologically isolated 309 
wetland prior to discharge. While no measurements of pharmaceuticals occurred during the 310 
winter, we note that this shallow wetland system and the offshore locations are predominantly or 311 
completely frozen over the winter. This would presumably result in no removal of analytes by 312 
either microbial activity or photodegradation (i.e., light penetration would be prevented almost 313 
completely by ice cover) until summer melt. 314 
The greatest concentration of sulfamethoxazole was 274 ng/L; this was detected at the 315 
Lagoon Input 2 site during wastewater discharge. Concentrations between lagoon sites were 316 
significantly different both before and during discharge (p<0.05), with some attenuation 317 
observed after wetland treatment, reaching 151 ng/L (45% removal, p<0.05). Levels offshore 318 
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were non-detectable both before and during discharge. Unlike this study, Conkle et al. (2008) 319 
noted over 90% removal of sulfonamides on a temperate wastewater facility, however, the 320 
differences may have been as a result of significantly greater temperatures and a 27-day retention 321 
period compared to a drastically colder weather and shorter retention time at Cambridge Bay 322 
facility of 1-2 days 323 
Trimethoprim was detected in concentrations under 30 ng/L at the lagoon and wetland 324 
sites. During wastewater release, the wetland concentration was 9.8 ng/L after significant 325 
attenuation (p<0.05) occurred between the lagoon and the wetland. Finally, clarithromycin and 326 
metoprolol were detected at both of the lagoon sites and also in the wetland at levels below LOQ. 327 
At the offshore sites, both compounds were non-detectable, which is consistent with what was 328 
observed for all contaminants studied. 329 
The presence or absence of specific pharmaceuticals depends partially on the residence 330 
time within sewage holding tanks, prior to entry into sewage lagoons. While photodegradation is 331 
unable to occur in septic tanks, other degradative processes like anaerobic microbial-mediated 332 
biotransformation could occur. Consequently, the most labile compounds were likely partially 333 
degraded to an unknown extent. Sorption of pharmaceuticals to septic tank particulates may also 334 
occur. Photodegradation and biotransformation are typically the most important processes for the 335 
attenuation of organic micropollutants in effluent-receiving waters. Consequently, optimization 336 
of conditions for these processes (e.g. by using extended periods of treatment in sewage lagoons) 337 
can effectively minimize or prevent environmental exposure to biologically active levels of these 338 
contaminants (Ying et al., 2009). 339 
To the best of our knowledge, there are no reported data for pharmaceuticals from 340 
wastewater systems from Northern Canada. Nevertheless, a larger amount of information (Table 341 
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3) is available for treated lagoon wastewaters using passive sampling of more southern regions in 342 
Canada, including various works done in the province of Manitoba (Anderson et al., 2013; 343 
Anderson et al., 2015; Carlson et al., 2013) and Alberta (MacLeod and Wong, 2010). At 344 
Cambridge Bay, all detectable compounds had greatest concentrations at either the lagoon or the 345 
wetland sites and were mostly non-detectable at locations offshore. Atenolol, carbamazepine, 346 
sulfamethoxazole and trimethoprim were detected in the Cambridge Bay facility at lower levels 347 
compared to the data obtained at Dunnottar, Manitoba (Anderson et al., 2015). On the other 348 
hand, atenolol, sulfamethoxazole and trimethoprim were detected in greater levels than in the 349 
Grand Marais wastewater treatment facility. Levels of drugs were similar in wastewaters of 350 
Cambridge Bay and Lac la Biche, Alberta (MacLeod and Wong, 2010).   351 
There are several factors that likely account for the differences in pharmaceutical levels 352 
among these locations.  One factor is population, with greater populations implying greater 353 
loadings and impact on wastewater release. The populations served by the treatment facilities of 354 
the southern Canadian sites (Table 3) are all on the order of several thousand, with some 355 
seasonal variability.  For example, the Dunnottar population, a popular regional summer resort 356 
(Anderson et al., 2015) is several times greater than that of Cambridge Bay during the summer.  357 
However, similar per capita use of drugs may result in similar concentrations in wastewaters 358 
(MacLeod and Wong, 2010), which appears to be the case based on our comparisons (Table 3).  359 
Another factor is temperature, given the fact that colder temperatures in Nunavut can cause 360 
treatment mechanisms such as sorption to be slower and less efficient when compared to 361 
temperate locations, as it has been previously observed in Norway (Kallenborn et al., 2008).  362 




3.3. Risk assessment for detected pharmaceuticals 365 
Hazard quotients (HQs) were calculated for each organic contaminant based upon toxicity 366 
data reported in the literature for primary producers, invertebrates and fish (Table S3). Most 367 





clarithromycin presented an HQ greater than 1 for the algae Pseudokirchneriella subcapita, 369 
which indicates that there is a potential for growth inhibition of algal species at concentrations 370 
such as those detected in lagoon and in the wetland. While the HQ for clarithromycin was greater 371 
than 1, the concentration level used for calculation may not be necessarily representative of what 372 
could be found in the entire lagoon, the use of 1000-fold uncertainty factor adds a high degree of 373 
conservatism. As well, in euthrophic environments, such as these lagoons, excess nutrients can 374 
mitigate the effects of compounds that exhibit herbicidal activity (Baxter et al., 2013). For the 375 
rest of the detected pharmaceuticals, we can conclude that there is likely no significant hazard to 376 
aquatic life due to the low concentrations at which they were detected. We did lack Arctic and 377 
marinespecific tests that would reduce the uncertainty and did not assess for the effect of 378 
mixtures of chemical stressors. We do recommend the development of standard toxicity tests 379 
with Arctic marine organisms to help address this uncertainty 380 
 381 
3.4. Abundances and removal of ARGs 382 
Total bacterial populations were determined by means of the abundances of 16S rRNA 383 
genes. Their presence was greatest in the lagoon sites in both sampling periods: before the 384 
wastewater discharge started (10
8.0
 genes/mL in Lagoon Input 1 and 10
7.8
 copies/mL in Lagoon 385 
Input 2), and during wastewater discharge (10
7.4
 genes/mL in Lagoon Input 1 and 10
7.5
 386 
copies/mL in Lagoon Input 2) (Table 2). Overall, the abundances of 16S rRNA genes were 387 
18 
 
similar (i.e., differences found were not greater than one order of magnitude) to levels reported at 388 
more southern locations in Canada (Anderson et al., 2015). Comparing concentrations before and 389 
during wastewater discharge, gene abundances did not change significantly (paired t-test, t5 = -390 
1.46, p = 0.203) and their distribution pattern remained similar (r = 0.965, p = 0.002) along the 391 
waste stream. 392 
Clusters of tetracycline resistance and sulfonamide-resistance genes were analyzed and the 393 
results were summed to facilitate assessment of resistance patterns. The greatest abundances of 394 
tet
R
 (sum of tetracycline resistance genes) and sul
R
 (sum of sulfonamide resistance genes) were 395 
found in the primary lagoon, at the two wastewater drop-off locations, being Lagoon Input 2 the 396 
one with the greatest response, with some attenuation through the wetland (Table 2).  397 
Specifically in terms of the tetracycline resistance genes, differences from lagoon levels to 398 
offshore levels were around one order of magnitude during discharge, with locations after the 399 
wetland having reductions most likely due to dilution. Outfall was the sampling spot with the 400 
lower amount of tet
R
 genes before and after discharge. Distribution of concentrations before and 401 
during discharge was similar (r = 0.941, p = 0.005), but became lower after discharge (paired t-402 
test, t5 = 3.66, p = 0.015) quite possibly due to dilution with water from the environment (e.g. 403 
existing surface water and/or groundwater seeps) 404 
Sulfonamide resistance genes were more highly concentrated in the lagoon and wetland, 405 
and before discharge declined rapidly (2-3 orders of magnitude) following the wetland. During 406 
discharge, gene concentrations were variable at the two drop-off points in the lagoon, with 407 
minimum to no attenuation from the wetland. Gene distribution patterns along the waste stream 408 
were comparable (before-during discharge; r = 0.887, p = 0.019), but unlike Ôtotal tetÕ there 409 
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were significant pairwise changes (paired t-test, t = 0.506, p = 0.634) as most concentrations 410 
decline, except at the wetland and slightly in CHARS site. 411 
To facilitate further analysis in prevalence of bacteria throughout the treatment process, 412 
abundances of resistance genes were divided by the abundance of 16S rRNA genes to represent 413 
relative gene abundances. Relative abundances of ARGs were low (e.g. less than 2% of the total 414 
as observed in the wetland) at all locations during discharge (see Table 2), which suggests a low 415 
potential for ARG-bearing bacteria to exist throughout the treatment system. Tetracycline 416 
resistance genes remain elevated in wastewater systems if there is a source of resistance 417 
microorganism and tetracycline usage (Peak et al., 2007), but can decline in sunlight-exposed 418 
systems over a relatively short period of time (Engemann et al., 2008; Zhang et al., 2009). This 419 
suggests that tetracycline may not have been extensively used in the Cambridge Bay population 420 
around the times of sampling. Gene concentrations were equivalent to wastewater lagoons with 421 
minimal tetracycline usage by source population e.g., (Peak et al., 2007), and could already 422 
represent near background levels (Engemann et al., 2006; Zhang et al., 2009). Whereas, 423 
detectable sulfonamide concentrations in this study may have been sufficient to maintain 424 
selective pressure for antibiotic-resistant bacteria, or their presence of elevated levels represent 425 
residual evidence of previously higher levels of sulfonamide usage, as gene fate tends to differ 426 
from chemical fate (e.g. Engemann et al., 2006; Peak et al., 2007) 427 
Wastewater systems have a variable ability to reduce antimicrobial resistance, given the 428 
fact that generally resistant bacteria numbers decline in wastewater treatment as bacteria are 429 
removed, but these patterns require further investigation, as they remain a function of bacterial 430 
community and operating conditions (Christgen et al., 2015). Further, no studies to date have 431 
examined the fate of antibiotic resistant bacteria in the wastewater stream at lower temperatures, 432 
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such as in the Arctic. Well-studied coliform bacteria, which tend to carry ARGs, persist longer in 433 
colder temperatures (Solic and Krstulovic, 1992); however, gene persistence at lower 434 
temperatures could be exacerbated by slowed transformation rates of pharmaceutical compounds 435 
and prolonged selective pressures, reduced endonuclease activity, and lowered predation. Further 436 
investigations are required to fully elucidate gene fate under psychrophilic conditions. 437 
 438 
Conclusions 439 
Our assessment of the Cambridge Bay wastewater treatment facility allowed us to detect 440 
no apparent removal of nutrients as a result of lagoon-wetland treatment. Reduced nutrients 441 
concentrations at locations offshore occurred as a result of dilution. Our data suggests that some 442 
attenuation mechanisms for pharmaceuticals exist in the treatment system, especially in the 443 
sewage lagoon and to some extent in the natural wetland. Distribution of the wastewater 444 
contaminants within the lagoon sites was not homogeneous, due to the presence of two different 445 
drop off points for sewage dumping and the topography of the lagoon. From all of the studied 446 
pharmaceuticals, only carbamazepine showed some persistence during the Arctic winter. 447 
Atenolol, sulfamethoxazole and trimethoprim had dissipated prior to the first sampling 448 
campaign. Concentrations of detected pharmaceuticals and nutrients were minimal in the Finger 449 
Bay location, which suggests that there was minimal runoff of wastewater to this point. Hazard 450 
assessment for detected pharmaceuticals shows that current concentrations of monitored 451 
pharmaceuticalsdo not pose a significant hazard at this time to aquatic organisms in Cambridge 452 
Bay. Bacterial populations were detected in similar levels to more southern Canadian locations, 453 
with some ARGs attenuation observed in the lagoon-wetland system and considerable dilution at 454 
locations offshore. Finger Bay experienced non-detectable levels for all pharmaceuticals and 455 
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very low levels of ARGs, which suggests that this location was not likely experiencing any 456 
sewage leaking at the time of this study. Overall, the CHARS scientific water supply location 457 
showed non-detectable levels for all pharmaceuticals and very low levels of ARGs, prior to the 458 
instalment of the facility at Cambridge Bay. This study constitutes one of first attempts ever 459 
made to understand the occurrence of pharmaceuticals, ARGs and nutrients on wastewater 460 
treatment facilities in the Canadian Arctic, as well as the removal performance of these systems 461 
under polar conditions. 462 
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Levels of total phosphorus and total nitrogen in the Cambridge Bay wastewater facility before 476 
and during wastewater discharge (n=1). Wastewater was grab-sampled on July 25 and September 477 
3, 2014. The limit of detection (LOD) and limit of quantification (LOQ) values for total nitrogen 478 
were 8 µg/L and 27 µg/L, and those for total phosphorus were 0.58 µg/L and 1.85 µg/L, 479 
respectively. 480 












Lagoon Input 1 2.4 12.6 2.8 12.0 
Lagoon Input 2 2.4 16.6 2.8 13.5 
Wetland 0.7 0.4 2.5 13.3 
Outfall 0.01 0.3 0.07 0.4 
Finger Bay 0.01 0.3 0.03 0.3 







Abundances of antibiotic resistance genes (log(genes/mL)) harvested from grab-samples taken at 485 
the Cambridge Bay wastewater treatment facility and receiving waters in 2014; standard 486 
deviation of sample replicates (n=3) are denoted in parentheses. Relative abundance of ARGs to 487 
16S rRNA, calculated during discharge (A = tetR/16S rRNA ratio, B = sulR/16S rRNA ratio) is 488 
also shown.  489 
 Before discharge During discharge 













Lagoon Input 1 4.2 (0.3) 4.7 (0.5) 8.0 (0.5) 3.8 (0.2) 4.4 (0.3) 7.4 (0.4) 0.02 0.1 
Lagoon Input 2 4.3 (0.3) 6.0 (0.7) 7.8 (0.9) 4.1 (0.3) 5.6 (0.3) 7.5 (0.8) 0.03 1.3 
Wetland 3.9 (0.2) 4.4 (0.3) 6.8 (0.4) 3.8 (0.2) 5.6 (0.3) 7.3 (0.6) 0.03 2.0 
Outfall 2.9 (0.2) 2.8 (0.2) 5.4 (0.4) 2.7 (0.2) 1.8 (0.1) 6.1 (0.4) 0.04 0.01 
Finger Bay 3.0 (0.1) 2.8 (0.2) 5.3 (0.2) 2.7 (0.2) 2.0 (0.2) 6.3 (0.4) 0.02 0.01 





Comparison of concentrations of target pharmaceutical compounds in treated wastewaters of 492 
different Canadian lagoon wastewater systems (NA: not analyzed, ND: non-detectable).  Lac la 493 
Biche data from MacLeod and Wong (2010), Dunnottar data from Anderson et al. (2015), Grand 494 
Marais data from Anderson et al. (2013), Cambridge Bay, this study. Populations are shown 495 
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Figure 1. Sampling site locations at the Cambridge Bay wastewater treatment facility and 501 
receiving waters. Wastewater path from the lagoon to the bay is shown by means of a dotted line. 502 
 503 
Figure 2. Mean levels of pharmaceuticals in Cambridge Bay wastewater facility, before and 504 
during the wastewater discharge process (n=3). Error bars depict the standard deviation on each 505 
case. Differences are significant for p < 0.05 and were assessed using paired t-tests. Wastewater 506 
was collected using Polar Organic Chemical Integrative Samplers from July 25 to August 8, 507 
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